Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + Atezolizumab in PD-L1-selected NSCLC
NCT04294810Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 23
01
Overview
A Phase 3 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Mar 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04294810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294810.